Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene

Slides:

Advertisements

Similar presentations

© 2005 Prentice Hall Inc. / A Pearson Education Company / Upper Saddle River, New Jersey Lung Cancer and Gefitinib  Lung cancer statistics in the.

Advertisements

Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.

Epidermal growth factor receptor (EGFR) mutations in NSCLC

Volume 206, Issue 3, Pages (March 2013)

Volume 18, Issue 6, Pages (September 2015)

Defining Epidermal Growth Factor Receptor exon 20 mutant sensitivity to tyrosine kinase inhibition Danny Rayes.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Fig. 1. EGFR content as determined by fluorescence in situ hybridization (FISH) and immunohistochemical staining. FISH was performed with the EGFR ( red.

Figure 3. Representative pyrosequencing results for EGFR gene mutations. (A) Case with 10.9% mutation frequency for the L858R mutation in EGFR exon 21.

Epidermal Growth Factor Receptor Mutation in a Patient with Squamous Cell Carcinoma of the Lung: Who Should Be Tested Case Rep Oncol 2013;6:

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.

From: Comparison of High-Resolution Melting Analysis with Denaturing High-Performance Liquid Chromatography for Mutation Scanning in the ABCA4 Gene Invest.

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Acrometastasis from an epidermal-growth-factor-receptor (EGFR) mutation-positive lung adenocarcinoma Mau-Ern Poh, Chong-Kin Liam, Jiunn-Liang Tan, Yong-Kek.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Testing algorithm integrating diagnostic and predictive analysis in nonsmall cell lung cancer (NSCLC). Testing algorithm integrating diagnostic and predictive.

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

Fundamental Concepts in the Diagnosis of Advanced NSCLC

Regulatory Industry Statistics Workshop 2018

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

Fig. S1 PIPKI is highly expressed in cancer cell lines

A Multiplex SNaPshot Assay as a Rapid Method for Detecting KRAS and BRAF Mutations in Advanced Colorectal Cancers Sandrine Magnin, Erika Viel, Alice.

Volume 9, Issue 6, Pages (June 2006)

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations Tae Jung Kim, MD, PhD, Choon-Taek.

Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity

Transbronchial Biopsy Needle Rinse Solution Used for Comprehensive Biomarker Testing in Patients with Lung Cancer Yuichi Sakairi, MD, PhD, Kenichi Sato,

Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers Yung-Chie Lee, MD, PhD, Yih-Leong Chang, MD, Shi-Ping.

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Volume 9, Issue 6, Pages (June 2006)

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer David R. Gandara, MD,

Uterine metastasis of lung adenocarcinoma revealed by the same epidermal growth factor receptor mutation in both lung and endometrial biopsies Noriko.

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

How I Do It—Optimal Methodology for Multidirectional Analysis of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples Takahiro Nakajima,

Inherited Germline T790M Mutation and Somatic Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer Patients Carmelo Tibaldi, MD,

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung.

Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based.

Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.

A novel method for the rapid and prospective identification of Beijing Mycobacterium tuberculosis strains by high-resolution melting analysis M. Alonso,

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Pyrosequencing Analysis of EGFR and KRAS Mutations in EUS and EBUS-Derived Cytologic Samples of Adenocarcinomas of the Lung Jos A. Stigt, MD, Nils A.

Representative CT and PET/CT images of three patients with NSCLCs

Clinical courses of patients.

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Erratum Journal of Thoracic Oncology

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

First Case of A859T Epidermal Growth Factor Receptor Mutation Responding to Erlotinib Laureline Le Maignan, BM, Delphine Mirebeau-Prunier, MD, PhD, Laurent.

Aglaya G. Iyevleva, MD, PhD Journal of Thoracic Oncology

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung Adenocarcinomas Qiulu Pan, William Pao, Marc.

Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) for EGFR mutant lung adenocarcinoma.

Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation Yao-Wen Kuo, MD, Shang-Gin Wu, MD, Chao-Chi.

Figure S1. A. B. Figure S1. Kaplan-Meier curve of progression-free survival by treatment group in soluble heregulin (HRG)-high population (A) and soluble.

Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas.

CHCHD2 and EGFR protein expression in NSCLC

Representative CT and PET/CT images of three patients with NSCLCs

Kaplan–Meier curve for progression-free survival for non-Asian patients with epidermal growth factor receptor (EGFR) mutation-positive status in the INTEREST.

Prevalence of germline T790M.

Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.

Epidermal Growth Factor Receptor Gene Mutation and Computed Tomographic Findings in Peripheral Pulmonary Adenocarcinoma Motoki Yano, MD, PhD, Hidefumi.

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene. (A) Temperature shift observed in the melting curves of a NSCLC sample with a mutation in exon 21 of the EGFR and a NSCLC sample with a wild-type EGFR. Each sample was analysed in triplicate. (B) Fluorescence difference curves of the same samples depicted in A. The NSCLC sample with a mutation in EGFR exon 21 is a moderately differentiated adenocarcinoma from a non-smoking woman. NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor. Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene. (A) Temperature shift observed in the melting curves of a NSCLC sample with a mutation in exon 21 of the EGFR and a NSCLC sample with a wild-type EGFR. Each sample was analysed in triplicate. (B) Fluorescence difference curves of the same samples depicted in A. The NSCLC sample with a mutation in EGFR. . . Yonsei Med J. 2016 Jan;57(1):50-57. http://dx.doi.org/10.3349/ymj.2016.57.1.50